INNATE PHARMA (EPA:IPH) Innate Pharma announces that it will participate to the MidCap Event on 21-22 September, 2009. Furthermore, Innate will host a conference call on Monday 21, detailing interim clinical results for IPH 1101 presented at the ESMO congress

Transparency directive : regulatory news

17/09/2009 18:46

PRESS RELEASE

            INNATE PHARMA ANNOUCES ITS PARTICIPATION TO THE MIDCAP EVENT

                     September 21 and 22, 2009, Paris, France

* Hervé Brailly, CEO of Innate Pharma, and Stéphane Boissel, Executive Vice
  President and Chief Financial Officer, will present the Company to the
  investors

* Upon the occasion of the announcement of interim clinical results for
  IPH 1101 at the ESMO congress on Monda y 21, the Company will host a con
  ference call at 2:30pm on that same day

Marseilles, France, September 17, 2009

Innate Pharma (Euronext Paris: FR0010331421 - IPH) announces today that it
will participate to the MidCap Event, a conference dedicated to meetings with
companies listed on NYSE-EURONEXT and investors, on September 21 and 22, 2009,
in Paris, France.

During this event, Hervé Brailly, CEO of Innate Pharma, and Stéphane Boissel,
Executive Vice President and Chief Financial Officer, will meet institutional
investors to present Innate Pharma, its development strategy and its latest
news.

Furthermore, upon the occasion of the announcement on September 21, 2009, of
interim clinical results for IPH 1101, its most advanced drug-candidate at the
international ESMO (European Society of Medical Oncology) congress, Innate
Pharma will host a conference call on the same day at 2:30 pm (Paris time).
Details to connect to this call will be communicated on the Company's website
as well as on a Monday press release.

About Innate Pharma:

Innate Pharma S.A. ("the company") is a clinical-stage biopharmaceutical
company developing first-in-class immunotherapy drugs for cancer and other
severe diseases. The company was incorporated in 1999 and listed on
NYSE-Euronext in Paris in 2006.

The company has significant expertise in identifying new targets and bringing
novel drug candidates through to clinical proof-of-concept trials. It
currently has seven proprietary drug candidates in development (two of which
are in Phase II clinical trials) and two programs out-licensed to Novo
Nordisk A/S.

Innate Pharma is based in Marseilles, France, and had 86 employees as at
June 30, 2009.

Learn more about Innate-Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code         FR0010331421

Ticker code       IPH

Disclaimer:
This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ
from those contained in the forward-looking statements, please refer to
the Risk Factors ("Facteurs de Risque") section of the Document de
Reference prospectus filed with the AMF, which is available on the AMF
website (http://www.amf-france.org) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country.

For additional information, please contact:
Innate Pharma                     Alize Public Relations
Laure-Hélène Mercier              Caroline Carmagnol
Director, Investor Relations      Phone: +33 (0)1 41 22 07 31
Phone: +33 (0)4 30 30 30 87       Mobile: +33 (0)6 64 18 99 59
investors@innate-pharma.com   caroline@alizerp.com

IPH_MidCap event

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) Innate Pharma announces that it will participate to the MidCap Event on 21-22 September, 2009. Furthermore, Innate will host a conference call on Monday 21, detailing interim clinical results for IPH 1101 presented at the ESMO congress

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories